SANCTURA XR- trospium chloride
capsule, extended release
Physicians Total Care, Inc.
SANCTURA XR ® is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The recommended dosage of SANCTURA XR ® is one 60 mg capsule daily in the morning. SANCTURA XR ® capsules should be dosed with water on an empty stomach, at least one hour before a meal.
SANCTURA XR ® is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/minute) (see Warnings and Precautions (5), Use in Specific Populations (8), and Clinical Pharmacology (12)).
SANCTURA XR ® is supplied as 60 mg capsules (white opaque body and orange opaque cap, printed with SAN 60).
SANCTURA XR ® is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. SANCTURA XR ® is also contraindicated in patients who have demonstrated hypersensitivity to the drug or any of its ingredients.
SANCTURA XR ® capsules should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention (see Contraindications (4)).
Angioedema of the face, lips, tongue and/or larynx has been reported with trospium chloride. In one case, angioedema occurred after the first dose of trospium chloride. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, trospium chloride should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.
SANCTURA XR ® should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention. SANCTURA XR ® , like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis (see Contraindications (4)).
In patients being treated for narrow-angle glaucoma, SANCTURA XR ® should only be used if the potential benefits outweigh the risks, and in that circumstance only with careful monitoring (see Contraindications (4)).
SANCTURA XR ® is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/minute) (see Dosage and Administration (2), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)).
Alcohol should not be consumed within 2 hours of SANCTURA XR ® administration. In addition, patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents.
The data described below reflect exposure to SANCTURA XR ® capsules in 578 patients for 12 weeks in two Phase 3 double-blind, placebo controlled trials (n=1165). These studies included overactive bladder patients of ages 21 to 90 years, of which 86% were female and 85% were Caucasian. Patients received 60 mg daily doses of SANCTURA XR ®. Patients in these studies were eligible to continue treatment with SANCTURA XR ® 60 mg for up to one year. From both these controlled trials combined, 769 and 238 patients received treatment with SANCTURA XR ® for at least 24 and 52 weeks, respectively.
There were 157 (27.2%) SANCTURA XR ® patients and 98 (16.7%) placebo patients who experienced one or more double-blind treatment-emergent adverse events (TEAEs) that were assessed by the investigator as at least possibly related to study medication. The most common TEAEs were dry mouth and constipation which, when reported, commonly occurred early in treatment (often within the first week). In the two Phase 3 studies, constipation, dry mouth, and urinary retention led to discontinuation in 1%, 0.7%, and 0.5% of patients treated with SANCTURA XR ® 60 mg daily, respectively. In the placebo group, there were no discontinuations due to dry mouth or urinary retention and one due to constipation.
The incidence of serious adverse events was similar among patients receiving SANCTURA XR ® and patients receiving placebo. No treatment-emergent serious adverse events in either treatment group were judged by the investigators as being possibly related to the study medication.
Table 1 lists those treatment emergent adverse events from the trials that were assessed by the investigator as possibly related to study medication, reported in at least 1% of SANCTURA XR ® patients, and were more common for the SANCTURA XR ® group than for placebo.
|MedDRA Preferred term||Number of patients (%)|
|Placebo N=587||SANCTURA XR ® N=578|
|Dry mouth||22 (3.7)||62 (10.7)|
|Constipation||9 (1.5)||49 (8.5)|
|Dry eye||1 (0.2)||9 (1.6)|
|Flatulence||3 (0.5)||9 (1.6)|
|Nausea||2 (0.3)||8 (1.4)|
|Abdominal pain||2 (0.3)||8 (1.4)|
|Dyspepsia||4 (0.7)||7 (1.2)|
|Urinary tract infection||5 (0.9)||7 (1.2)|
|Constipation aggravated||3 (0.5)||7 (1.2)|
|Abdominal distension||2 (0.3)||6 (1.0)|
|Nasal dryness||0 (0.0)||6 (1.0)|
Additional adverse events reported in less than 1% of SANCTURA XR ® - treated patients and more common for SANCTURA XR ® than placebo, judged by the investigator at least possibly related to treatment were: vision blurred, feces hard, back pain, somnolence, urinary retention, and dry skin.
Table 2 lists all treatment-emergent adverse events for the trials reported in at least 2% of all SANCTURA XR ® patients and more common for the SANCTURA XR ® group than for placebo without regard to the investigator’s judgment on drug relatedness.
|MedDRA Preferred term||Number of patients (%)|
|Placebo N=587||SANCTURA XR ® N=578|
|Dry mouth||22 (3.7)||64 (11.1)|
|Constipation||10 (1.7)||52 (9.0)|
|Urinary tract infection||29 (4.9)||42 (7.3)|
|Nasopharyngitis||10 (1.7)||17 (2.9)|
|Influenza||9 (1.5)||13 (2.2)|
Additional adverse events reported in less than 2% of SANCTURA XR ® - treated patients and twice as frequent for SANCTURA XR ® compared to placebo, regardless of reported relationship to treatment were: tachycardia, dry eyes, abdominal pain, dyspepsia, abdominal distension, constipation aggravated, nasal dryness, and rash.
In the open-label treatment phase, the most common TEAEs reported in the 769 patients with at least 6 months exposure to SANCTURA XR ® were: constipation, and dry mouth. Urinary tract infection and rash was also reported in several patients, including one of each judged by the investigator to be possibly related to treatment. Several adverse events were reported as severe in the open-label treatment phase, including one urinary tract infection, two urinary retention events, and one aggravated constipation.
The effect of 20 mg twice daily and up to 100 mg twice daily of an immediate-release formulation of trospium chloride on QT interval was evaluated in a single-blind, randomized, placebo and active (moxifloxacin 400 mg daily) controlled, 5-day parallel trial in 170 male and female healthy volunteer subjects aged 18 to 45 years. The QT interval was measured over a 24-hour period at steady state. Trospium chloride was not associated with an increase in individual corrected (QTcI) or Fridericia corrected (QTcF) QT interval at any time during steady state measurement, while moxifloxacin was associated with a 6.4 msec increase in QTcF.
In this study, asymptomatic, non-specific T-wave inversions were observed more often in subjects receiving trospium chloride than in subjects receiving moxifloxacin or placebo following five days of treatment. The clinical significance of T-wave inversion in this study is unknown. This finding was not observed during routine safety monitoring in overactive bladder patients from 2 placebo-controlled clinical trials in 591 patients treated with 20 mg twice daily of immediate-release trospium chloride, nor was it observed in 2 placebo-controlled clinical trials in 578 patients treated with SANCTURA XR ® capsules.
Also in this study, the immediate-release formulation of trospium chloride was associated with an increase in heart rate that correlated with increasing plasma concentration, with a mean elevation in heart rate compared to placebo of 9 beats per minute for the 20 mg dose and of 18 beats per minute for the 100 mg dose. In the two Phase 3 SANCTURA XR ® trials the mean increase in heart rate compared to placebo was approximately 3 beats per minute in both studies.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.